phenobarbital has been researched along with tacrolimus in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Beck, WT; Schuetz, EG; Schuetz, JD | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Prasad, TN; Stiff, DD; Venkataramanan, R | 1 |
| Domergue, J; Fabre, I; Joyeux, H; Maurel, P; Pichard, L | 1 |
| Almeidal, VM; Braun, F; Christians, U; Linck, A; Sattler, M; Sewing, KF | 1 |
| Hoyt, EG; Morris, RE; Murphy, MP; Shorthouse, R | 1 |
| Funae, Y; Iwasaki, K; Matsuda, H; Nagase, K; Noda, K; Shimada, T; Shiraga, T; Yamazaki, H | 1 |
| Gelman, B; Kato, T; McLaughlin, GE; Rossique-Gonzalez, M | 1 |
| Bristow, LJ; Chang, IF; Goss, JA; Karpen, SJ; Quirós-Tejeira, RE | 1 |
| Adam, G; Fleck, C; Karge, E; Kuhn, UD; Lupp, A | 1 |
| Marfo, K; Siddiqi, N | 1 |
| Chen, J; Liu, W; Lu, X; Wang, N; Zhang, Y; Zhao, X; Zhu, L; Zuo, M | 1 |
1 review(s) available for phenobarbital and tacrolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
17 other study(ies) available for phenobarbital and tacrolimus
| Article | Year |
|---|---|
Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Blotting, Northern; Cell Line; Clotrimazole; Colonic Neoplasms; Cytochrome P-450 CYP2E1; Cytochrome P-450 Enzyme System; Dexamethasone; DNA Primers; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; Midazolam; Mixed Function Oxygenases; Molecular Sequence Data; Multigene Family; Phenobarbital; Phenytoin; Polymerase Chain Reaction; Rifampin; Tumor Cells, Cultured; Verapamil | 1996 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Metabolism of FK 506 in differentially induced rat liver microsomes.
Topics: Animals; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dexamethasone; Enzyme Induction; Enzyme Inhibitors; Isoenzymes; Male; Methylcholanthrene; Microsomes, Liver; Phenobarbital; Rats; Rats, Sprague-Dawley; Tacrolimus | 1992 |
Effect of FK 506 on human hepatic cytochromes P-450: interaction with CyA.
Topics: Cells, Cultured; Cyclosporine; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Induction; Humans; Isoenzymes; Liver; Microsomes, Liver; Phenobarbital; Rifampin; Tacrolimus | 1991 |
Interactions of FK 506 and cyclosporine metabolism.
Topics: Animals; Cyclosporine; Drug Interactions; Humans; Kinetics; Methylcholanthrene; Microsomes, Liver; Phenobarbital; Rats; Tacrolimus | 1991 |
Immunopharmacology of FK-506.
Topics: Animals; Cyclosporins; Cytochrome P-450 Enzyme System; Enzyme Induction; Graft Survival; Heart Transplantation; Host vs Graft Reaction; Immunosuppressive Agents; Liver; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Phenobarbital; Pyridines; Rats; Rats, Inbred BN; Rats, Inbred Lew; Tacrolimus; Transplantation, Homologous | 1989 |
Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes.
Topics: Animals; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Dogs; Female; Humans; Male; Microsomes, Liver; Mixed Function Oxygenases; Oxidation-Reduction; Phenobarbital; Rats; Rats, Sprague-Dawley; Tacrolimus | 1994 |
Use of phenobarbital in the management of acute tacrolimus toxicity: a case report.
Topics: Acute Disease; Fatal Outcome; Female; Humans; Immunosuppressive Agents; Infant; Liver Transplantation; Phenobarbital; Postoperative Complications; Renal Dialysis; Tacrolimus | 2000 |
Treatment of acute tacrolimus whole-blood elevation with phenobarbital in the pediatric liver transplant recipient.
Topics: Biliary Atresia; Half-Life; Humans; Immunosuppressive Agents; Infant; Liver Transplantation; Male; Phenobarbital; Tacrolimus | 2005 |
In vitro investigations on the differential pro-oxidant and/or antioxidant properties of cyclosporin A and tacrolimus in human and rat liver microsomes.
Topics: Animals; Antioxidants; beta-Naphthoflavone; Cyclosporine; Cytochrome P-450 Enzyme System; Dexamethasone; Dose-Response Relationship, Drug; Enzyme Induction; Humans; Hydrogen Peroxide; Immunosuppressive Agents; In Vitro Techniques; Isoenzymes; Lipid Peroxidation; Liver; Male; Microsomes, Liver; Oxidants; Phenobarbital; Rats; Rats, Wistar; Tacrolimus | 2006 |
Clinically significant drug-drug interaction between tacrolimus and phenobarbital: the price we pay.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Phenobarbital; Tacrolimus | 2010 |
Drug-drug interaction comparison between tacrolimus and phenobarbital in different formulations for paediatrics and adults.
Topics: Adult; Area Under Curve; Child; Drug Interactions; Humans; Immunosuppressive Agents; Models, Biological; Pediatrics; Pharmaceutical Preparations; Phenobarbital; Tacrolimus | 2021 |